Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial

Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable melanoma. Watch Prof. Georgina Long’s interview on the CheckMate 915 study results – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma Questions: What are the hot topics and clinical trial highlights in melanoma from ESMO 2022? (0:11) Disclosures: Georgina Long has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.